|Last Updated: January 19, 2019 @ 10:13 am|
|Stability:||Ambient: 2 Hour(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable|
|Interpretive Data:||General Reference Range : 0-38.1 U/mL|
The Roche e601 CA 125 electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. The CA 125 assay is used as an aid in monitoring response to therapy for patients with epithelial ovarian cancer. Serial testing for patient CA 125 values should be used in conjunction with other clinical methods for monitoring ovarian cancer. Patients with confirmed ovarian carcinoma may have pretreatment CA 125 assay values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. For these reasons, a CA 125 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.